| Open Document File Size: 1,42 MBShare Result on Facebook
City Reference / / Company Merck / / Country Colombia / United States / Estonia / Costa Rica / / Event FDA Phase / / IndustryTerm well-characterized drug product / drug product / / MedicalCondition conduction system disease / hypertrophic cardiomyopathy / chronic pulmonary disorder / chronic treatment / shortness of breath / perennial allergic rhinitis / heart disease / anaphylaxis / upper respiratory infection / clinically significant illness / allergic rhinitis / seasonal allergic rhinitis / Exercise-Induced Bronchospasm / hypersensitivity / illness / bronchoconstriction / exercise-induced bronchoconstriction / upper respiratory tract infection / asthma / / MedicalTreatment birth control / Antibiotics / Immunotherapy / / Organization Pediatric Review Committee / MEDICAL OFFICER REVIEW Division of Pulmonary and Allergy Drug Products / / Person Jennifer Rodriguez Pippins / Susan Limb / / Position Investigator / TEAM LEADER / EXECUTIVE / MEDICAL OFFICER / / Product Chewable Tablets / Theophylline / Singulair / albuterol / hydroxyzine / hydrocortisone / Ketotifen / Rescue medication / granules / Singulair™ / Chewable / Allergy Drug / EFFICACY / Study Report PMC Study Report Efficacy Supplement / Singulair™ Oral Granules / Singulair™ (motelukast sodium) / /
SocialTag |
20829 Montelukast Clinical PREA